sur The Vanguard Group, Inc. (isin : US12572Q1058)
The Vanguard Group Discloses Position in Avadel Pharmaceuticals
The Vanguard Group, Inc. has released a Form 8.3 regarding its position in Avadel Pharmaceuticals plc. Dated February 11, 2026, this disclosure is in accordance with the Irish Takeover Panel's Rule 8.3. The document specifies Vanguard's interests in Avadel, detailing the ownership and dealings related to relevant securities.
As of February 10, 2026, Vanguard holds 5,396,577 ordinary shares of Avadel Pharmaceuticals, representing 5.54% of the company's issued share capital. The disclosure includes recent transactions, notably the purchase of 4,651 shares and sales totaling 280,779 shares, with share prices ranging from 21.63 to 21.68 USD.
No indemnity or agreements inducing dealings were noted, nor are there any arrangements affecting voting rights through options or derivatives. This report is integral to maintaining transparency in market positions and activities related to potential takeovers.
R. E.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de The Vanguard Group, Inc.